afro-nets
[Top] [All Lists]

[afro-nets] AMANET announces progress of the Phase II Clinical Trial of Candidate Malaria Vaccine GMZ2 to mark world malaria day

*AMANET announces progress of the Phase II Clinical Trial of Candidate
Malaria Vaccine GMZ2 to mark world malaria day***

The African Malaria Network Trust (AMANET) and the European and Developing 
Countries Clinical Trials Partnership (EDCTP) funded GMZ2 consortium 
undertaking clinical development of GMZ2 Malaria vaccine candidate, announce 
progress of the Phase II b trial in children aged 12 to 60 months. The 
consortium contains 4 work packages namely project management, clinical trials, 
capacity building and networking. As part of the clinical trials work package, 
the consortium partners are undertaking a multi centre phase II randomized 
controlled clinical trial of malaria vaccine candidate, GMZ2, which is a 
recombinant fusion protein of two *Plasmodium falciparum*proteins, glutamate 
rich protein and merozoite surface protein 3. The trial is ongoing at the 
Medical Research Unit (MRU) of the Albert Schweitzer Hospital (ASH) in 
Lambaréné, Gabon where around 463 children have already received their first 
dose and vaccination are foreseen to be completed in June. Three reports, by a 
data and safety monitoring board have shown that the trial and control vaccines 
were safe.

The initiation meeting of the GMZ2 trial took place at Centre National de 
Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso on 9thand 11 
th March, 2011, and was attended by the principal investigators from 4 other 
African countries (Uganda, The Gambia, Gabon and Ghana). Also attending this 
event were consortium members from London School of Hygiene and Tropical 
Medicine - EUKT, Tübingen University – Germany and Statens Serum Institut - 
Denmark. Around 460 children will be recruited in Banfora and in Saponé 
additional participants will be recruited if required. At the CNRFP, first 
vaccination will be given on 2nd May, 2011. Other participating centers namely 
Makerere University, Uganda and Navrongo Health Research Centre, Ghana will 
start vaccinations in the second quarter of 2011.

The partners in the GMZ2 vaccine consortium are AMANET, the Centre National de 
Recherche et de Formation sur le Paludisme (CNRFP), Burkina Faso; Statens Serum 
Institut (SSI), Denmark; the Medical Research Unit at Albert Schweitzer 
Hospital (MRU-ASH), Gabon; the Medical Research Council (MRC) Laboratories, The 
Gambia; University of Tübingen, Germany; Makerere University, Uganda; Navrongo 
Health Research Centre, Ghana; and the London School of Hygiene and Tropical 
Medicine (LSHTM), UK.

Phase I studies of GMZ2 have received support from the European Commission – 
AIDCO, EDCTP and the European Malaria Vaccine Initiative (EMVI) now called 
European Vaccine Initaitive (EVI). The phase II GMZ2 trials are funded by EDCTP 
with additional funds from member states [Denmark & Germany]. 

This trial is registered with PACTR [ATMR2010060002033537], a public 
registration system for Malaria, TB and HIV/AIDS research in Africa.

For further information on GMZ2 Consortium activities, kindly contact AMANET 
through the following;

Dr Dawit A. Ejigu, 
GMZ2 Coordinator, 
mailto:daejigu@amanet-trust.org

Dr Brenda Okech, 
GMZ2 Project Manager, 
www.amanet-trust.org/GMZ2
mailto:baokech@amanet-trust.org

<Prev in Thread] Current Thread [Next in Thread>
  • [afro-nets] AMANET announces progress of the Phase II Clinical Trial of Candidate Malaria Vaccine GMZ2 to mark world malaria day, Brenda Okech <=